Breast Cancer [BC]

From @Point of Care

Veröffentlicht von: @Point of Care

Beschreibung

Breast Cancer @Point of Care for clinicians provides a well-engineered clinical decision support tool for you to obtain timely medical content and news as well as earning CME/CE credits, completely free of charge. If used in conjunction with our PRO Patient line of apps for patients (35+ apps for major conditions), Suite can provide you meaningful insights into between-visit patient progress—driving better decisions, better outcomes, and better care.
The app features Ask Cognitive™, an AI-assisted search technology to easily access curated, evidence-based, and disease-specific medical content. Clinicians can navigate content by asking voice-enabled natural language questions or typing them in. The Ask Cognitive confidence-rated answers efficiently incorporate the best current treatment options so decisions can be reached confidently and more rapidly, helping to improve patient outcomes. Answers can also be further investigated for deeper dives.
Features:
• Continually updated breast cancer content from expert physician authors
• Customize library with over 50 therapeutic areas to choose from
• Topics in diagnosis, treatment, and care management
• Case studies, videos, and interviews
• Access to actionable patient-recorded data
• Detailed reference list with access to original sources
• Continuing medical education credit (CME/CE) free of charge
• Surveys and peer polling
• Patient education resources to share with patients
Breast Cancer @Point of CareTM is designed to:
• Support discovery and practice change
• Provide relevant, evidence-based disease-specific medical content
• Improve patient outcomes at the point of care
Target Audience:
This CME/CE program is intended for oncologists, obstetrician-gynecologists, radiologists, primary care clinicians, physician assistants, nurses, nurse practitioners, pharmacists, and other oncology healthcare team members that treat and care for patients with breast cancer.
Ausblenden Mehr anzeigen...

Screenshots

Breast Cancer [BC] Häufige Fragen

  • Ist Breast Cancer [BC] kostenlos?

    Ja, Breast Cancer [BC] ist komplett kostenlos und enthält keine In-App-Käufe oder Abonnements.

  • Ist Breast Cancer [BC] seriös?

    Nicht genügend Bewertungen, um eine zuverlässige Einschätzung vorzunehmen. Die App benötigt mehr Nutzerfeedback.

    Danke für die Stimme

  • Wie viel kostet Breast Cancer [BC]?

    Breast Cancer [BC] ist kostenlos.

  • Wie hoch ist der Umsatz von Breast Cancer [BC]?

    Um geschätzte Einnahmen der Breast Cancer [BC]-App und weitere AppStore-Einblicke zu erhalten, können Sie sich bei der AppTail Mobile Analytics Platform anmelden.

Benutzerbewertung
Die App ist in Schweden noch nicht bewertet.
Bewertungsverlauf

Breast Cancer [BC] Bewertungen

Keine Bewertungen in Schweden
Die App hat noch keine Bewertungen in Schweden.

Store-Rankings

Ranking-Verlauf
App-Ranking-Verlauf noch nicht verfügbar
Kategorien-Rankings
App ist noch nicht gerankt

Breast Cancer [BC] Konkurrenten

Name
Cancer Risk Calculator
Cancer Pharmacology Manual
Anticancer Oncology Drug Guide
Surviving Breast Cancer Org
My Risk Breast Cancer
Find your breast cancer risk
Breast Cancer Club
Triple Negative Breast Cancer
Testicular Cancer Staging
Urology Oncology
Mammography Assistant
Breast Cancer Staging
Esophageal Cancer Stage
Breast Cancer Survivorship

Breast Cancer [BC] Installationen

Letzte 30 Tage

Breast Cancer [BC] Umsatz

Letzte 30 Tage

Breast Cancer [BC] Einnahmen und Downloads

Gewinnen Sie wertvolle Einblicke in die Leistung von Breast Cancer [BC] mit unserer Analytik.
Melden Sie sich jetzt an, um Zugriff auf Downloads, Einnahmen und mehr zu erhalten.
This page includes copyrighted content from third parties, shared solely for commentary and research in accordance with fair use under applicable copyright laws. All trademarks, including product, service, and company names or logos, remain the property of their respective owners. Their use here falls under nominative fair use as outlined by trademark laws and does not suggest any affiliation with or endorsement by the trademark holders.